Self‐Reported Adverse Events Following COVID‐19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross‐Sectional Study
Health Science Reports,
Год журнала:
2025,
Номер
8(3)
Опубликована: Март 1, 2025
Accurate
and
transparent
investigation
of
adverse
events
(AEs)
following
COVID-19
vaccination
enhances
social
trust
confidence
in
programs.
This
study
aimed
to
assess
the
prevalence
vaccination-related
AEs
among
medical
sciences
students.
In
this
cross-sectional
study,
a
self-administered
survey
via
Google
Forms
was
conducted
evaluate
associated
with
AZD1222
(Oxford-AstraZeneca)
BBIBP-CorV
(Sinopharm)
vaccines
Data
were
collected
participation
training
program
focused
on
symptomatology
AEs,
which
designed
reduce
confirmation
bias.
A
total
263
students
from
North
Khorasan
University
Medical
Sciences,
Bojnurd,
Iran,
participated
data
collection
occurring
August
8
September
1,
2021.
The
median
age
population
23
years
(IQR:
22-24),
207
participants
being
female
(78.7%).
Following
first
dose,
significantly
more
common
Oxford-AstraZeneca
group
compared
Sinopharm
[OR
12.93
(5.57-30.03),
p
<
0.001].
However,
second
there
no
significant
difference
between
1.45
(0.86-2.46),
=
0.17].
Injection
site
pain,
fever,
body/muscle
headache,
feeling
unwell,
fatigue
most
both
vaccines,
variations
doses.
type
vaccine
sex
only
factors
influencing
AEs.
Notably,
odds
experiencing
higher
women
men.
findings
indicated
that
for
vaccine.
Further
research
is
necessary
explore
impact
utilizing
standardized
definitions
terminology
ensuring
accurate
consistent
reporting.
Язык: Английский
Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance
European Journal of Cardiovascular Nursing,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 5, 2025
Abstract
Aims
Concerns
have
been
raised
regarding
the
potential
causal
relationship
between
myocarditis
and
mRNA
COVID-19
vaccines.
In
response,
Korea
Disease
Control
Prevention
Agency
actively
monitored
pericarditis
in
adolescents
who
received
vaccines
South
Korea.
Understanding
long-term
health
outcomes
of
these
cases
is
essential
for
developing
evidence-based
national
policies.
We
aimed
to
identify
health-related
quality
life
(HRQoL)
through
follow-up
observations
this
population.
Methods
results
This
cross-sectional
descriptive
study
was
conducted
utilizing
a
self-reported
online
structured
survey.
Adolescents
diagnosed
with
or
after
receiving
vaccination
were
recruited
from
those
compensation
decisions
Agency.
Health-related
life,
depression,
anxiety,
subjective
status,
self-efficacy
measured,
correlations
differences
among
variables
analysed.
The
45
participants
obtained
an
average
HRQoL
score
81.6
out
100
points.
mean
depression
13,
44.4%
reporting
increase
depressive
symptoms,
following
their
diagnosis
pericarditis.
Anxiety,
2.96,
reported
increased
by
51.1%
diagnosis.
59.
Conclusion
These
suggest
that
individuals
experiencing
may
encounter
physical
psychological
challenges,
underscoring
need
comprehensive
support
evaluation.
Язык: Английский
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination
npj Vaccines,
Год журнала:
2025,
Номер
10(1)
Опубликована: Май 8, 2025
Язык: Английский
COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials
Vaccine,
Год журнала:
2025,
Номер
61, С. 127342 - 127342
Опубликована: Июнь 4, 2025
Язык: Английский
The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(23), С. 7291 - 7291
Опубликована: Ноя. 30, 2024
Clarifying
and
differentiating
the
causes
of
diseases
is
an
essential
step
in
any
clinical
activity,
but
it
takes
on
particular
relevance
complexity
case
that
arise
following
vaccinations.
The
WHO
has
proposed
a
protocol
uses
list
specific
questions
about
vaccine-related
adverse
events
algorithm
for
making
judgement.
Here,
we
analyze
discuss
important
limitations
this
when
applied
to
new
genetic-based
anti-COVID-19
vaccines,
particularly
once
dealing
with
rare
unexpected
pathological
events.
main
controversial
aspects
concern:
(a)
prevailing
consideration
other
possible
causes;
(b)
biological
plausibility
choice
appropriate
time
window
consider
effects
possibly
caused
by
vaccines;
(c)
reference
scientific
literature,
which
may
be
very
limited
often
early
stages
introducing
vaccines
because
short
period
observation;
(d)
final
classification
into
only
three
classes,
leaves
ample
space
"indeterminate"
category.
Failure
address
these
issues
lead
distorted
pharmacovigilance
reports
significant
consequences
benefit/harm
assessment.
In
anticipation
future
pandemics
managed
needs
revised
protocols
monitoring
evaluation
take
account
novel
mechanism
action
real-world
epidemiological
data.
Язык: Английский
COVID-19 Vaccine Safety Studies among Vulnerable Populations: A Systematic Review and Meta-analysis of 120 Observational Studies and Randomized Clinical Trials
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 29, 2024
Abstract
BACKGROUND
The
COVID-19
vaccines
were
rapidly
developed
and
tested,
but
concerns
about
vaccine-related
adverse
events
remain,
especially
in
vulnerable
groups
like
pregnant
women,
children,
those
with
certain
health
conditions.
This
review
aims
to
summarize
rates
of
such
individuals
often
not
included
randomized
clinical
trials
(RCT).
METHOD
From
December
2019
February
2022,
we
searched
Embase
Medline
for
observational
studies
RCTs
on
post-COVID-19
vaccination
groups.
We
examined
serious
non-serious
specific
medical
conditions,
infants,
individuals,
socioeconomically
disadvantaged
individuals.
Cumulative
risks
all
calculated.
Incidence
rate
(IR)
95%
confidence
intervals
reported
that
met
the
follow-up
period
criteria
based
referenced
literature.
For
data
exposed
unexposed
groups,
calculated
odds
ratio.
Pooled
incidence
per
1000
person-days
using
a
random-effects
model.
Sub-group
analyses
conducted
vaccine
types
doses,
heterogeneity
assessed
I
2
.
FINDINGS
Of
4,254
papers,
235
eligibility
criteria,
including
120
171,073
participants
(113
observational,
eight
RCTs.
17
severe
7
non-severe
event
categories.
Lymphadenopathy
(IR:
1.95[1.20;3.19]),
autoimmune
disease
multiple
sclerosis
flare-up
(1.13
[0.47;2.68]),
cardiac
symptoms
(0.26[0.00;10.58])
most
events.
Allergic
reactions
more
common
among
(7.03[4.10;12.06])
cancer
(4.87[2.21;10.76])
vaccinees
who
received
second
dose
had
higher
proportions
flare-ups
(39.27
[18.08;85.31]
vs
22.13
[10.22;
47.93]);
(6.11[2.05-18.22]
3.78[2.53-5.65]);
(5.34[1.69;16.90]
5.05[1.40,18.19])
studies.
INTERPRETATION
highlights
safety
populations,
enhancing
strategies.
Further
real-world
research
is
needed
validate
extend
our
findings,
addressing
gaps
Язык: Английский